News |

Study provides confidence in timeliness and sensitivity of AusVaxSafety

A new simulation study on Australia’s leading active vaccine safety surveillance system, AusVaxSafety, has been released that shows that the system is robust and would have detected a vaccine safety signal had it been operating in 2010 when there was an unprecedented number of febrile seizures in young children associated with one specific influenza vaccine brand, Fluvax (CSL Biotherapies). Fluvax was subsequently prohibited for use in children.

Read more on AusVaxSafety website. 



News & events

News |

New research urges coordinated action to reverse Australia’s declining childhood vaccination rates

News |

Building immunisation leadership in Fiji: national ‘training of trainers’ empowers health professionals

News |

There’s a new vaccine for pneumococcal disease in Australia. Here’s what to know
News |

Measles in Vietnam: breaking the cycle for good
News |

Australian Vaccinology Course launches with impact
News |

NCIRS Global Health: accelerating immunisation progress across Southeast Asia and the Pacific
News |

Receiving a recent COVID-19 booster prevents death in older people, NCIRS study shows

News |

SKAI engages parents to help close growing immunity gap among adolescents
News |

NCIRS study assesses clinical progression of myocarditis linked to mRNA COVID-19 vaccination
News |

New report sheds light on immunisation gaps across middle-income countries in Asia
All news & events